AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Phase 3positiveRepathaPositive
AI Analysis
Summary
Amgen announced that Repatha (PCSK9 inhibitor) reduced risk of death from all causes in high-risk primary prevention patients in a Phase 3 trial, marking the first PCSK9 inhibitor to demonstrate mortality benefit in this patient population.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Repatha reduced risk of death from all causes including cardiovascular events in high-risk primary prevention patients
Importance:8/10
Sentiment:
0.85
PCSK9 inhibitorcardiovascularprimary preventionmortality reductionPhase 3 trial
Related Companies
Read the original article
Published by PR Newswire Biotech on August 31, 2026 7:18 AM